億帆醫藥(002019)5月15日(ri)晚間公(gong)(gong)(gong)(gong)告,擬通(tong)過向全資(zi)子公(gong)(gong)(gong)(gong)司(si)(si)億帆國際現金增資(zi)或借款(kuan)的方式,用(yong)于(yu)其向賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)全體股(gu)東發起自(zi)愿(yuan)全面收(shou)購要(yao)約,擬要(yao)約收(shou)購賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)不低于(yu)90%的股(gu)份,包括可能要(yao)約收(shou)購賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)100%股(gu)權,使得賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)退市。此(ci)次要(yao)約收(shou)購賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)100%股(gu)權的對價約為(wei)2800.01萬美元。賽(sai)(sai)(sai)臻公(gong)(gong)(gong)(gong)司(si)(si)是一家在澳大利亞證(zheng)券交易(yi)所掛牌上市的新加坡生物醫藥公(gong)(gong)(gong)(gong)司(si)(si)。